| Literature DB >> 31866770 |
Christina Ekenbäck1, Fadi Jokhaji1, Nikolaos Östlund-Papadogeorgos1, Habib Mir-Akbari1, Rikard Linder1, Nils Witt2, Mattias Törnerud1, Bassem Samad1, Jonas Persson1.
Abstract
AIM: To investigate the relationship between stent length and changes in microvascular resistance during PCI in stable coronary artery disease (CAD). METHODS ANDEntities:
Mesh:
Year: 2019 PMID: 31866770 PMCID: PMC6913317 DOI: 10.1155/2019/1397895
Source DB: PubMed Journal: J Interv Cardiol ISSN: 0896-4327 Impact factor: 2.279
Baseline characteristics.
| Age, years (s.d.) | 65.3 (8.2) |
| Female gender, | 7 (17) |
| Diabetes mellitus, | 7 (17) |
| Previous myocardial infarction, | 5 (12) |
| Previous PCI, | 9 (21) |
| Atrial flutter, | 2 (5) |
|
| |
| Smoking, | |
| Never | 24 (57) |
| Previous | 13 (31) |
| Smoker | 5 (12) |
|
| |
| Canadian Cardiovascular Society grade, | |
| I | 15 (36) |
| II | 23 (55) |
| III | 3 (7) |
| IV | 1 (2) |
|
| |
| Body mass index (kg/m2), median (IQR) | 27 (24–30) |
| Total cholesterol (mmol/L), median (IQR) | 4.3 (3.7–5.1) |
| Low density lipoprotein cholesterol (mmol), median (IQR) | 2.4 (1.9–3.1) |
| HbA1c (mmol/mol), median (IQR) | 39 (35–42) |
| Creatinine clearance (mL/min/1.73 m2), median (IQR) | 82 (69–96) |
|
| |
| Medication at inclusion | |
| Aspirin | 42 (100) |
| Clopidogrel | 40 (95) |
| Ticagrelor | 2 (5) |
| AII-receptor antagonists, | 12 (29) |
| Beta-blockers, | 26 (62) |
| Nitrates, | 10 (24) |
| Calcium antagonists, | 13 (31) |
| ACE inhibitors, | 9 (21) |
| Lipid-lowering therapy at admission | 32 (76) |
IQR = interquartile range.
Procedural characteristics.
| Total stent length in LAD | ||||
|---|---|---|---|---|
| 12–22 mm | 23–37 mm | 38–78 mm | ||
|
|
|
| ||
| Number of stents in LAD | 1 | 14 | 9 | 5 |
| 2 | 0 | 5 | 7 | |
| 3 | 0 | 0 | 2 | |
|
| ||||
| Direct stenting (no predilatation) | Yes | 1 | 3 | 0 |
| No | 13 | 9 | 13 | |
|
| ||||
| Post dilatation | Yes | 7 | 9 | 14 |
| No | 7 | 5 | 0 | |
|
| ||||
| Largest stent in LAD (mm), median (IQR) | 3.5 (3–3.5) | 3.5 (3.5–3.5) | 3.5 (3–3.5) | |
| Smallest stent in LAD (mm), median (IQR) | 3.5 (3–3.5) | 3.5 (3–3.5) | 3 (2.75–3.5) | |
| Total stent length in LAD (mm), median (IQR) | 20 (16–20) | 29 (26–34) | 46 (38–54) | |
| Maximum dilatation pressure, median (IQR) | 20 (16–20) | 20 (16–20) | 20 (20–20) | |
IQR = interquartile range.
Flow indices in relation to total stent length in LAD.
| Total stent length in LAD | ||||
|---|---|---|---|---|
| 12–22 mm | 23–37 mm | 38–78 mm |
| |
| Before PCI | ||||
| Pa hyperaemia (mm Hg) | 82 (65–84) | 76 (61–87) | 72 (65–88) | 0.903 |
| Pd hyperaemia (mm Hg) | 58 (45–65) | 50.5 (40–67) | 49 (41–56) | 0.242 |
| FFR | 0.77 (0.69–0.80) | 0.74 (0.7–0.77) | 0.66 (0.46–0.74) | 0.002 |
| IMR† | 20 (11–27) | 16 (9–26) | 16 (10–20) | 0.557 |
| IMRcorr† | 19 (10–25) | 14 (8–24) | 14 (10–18) | 0.329 |
| CFR | 2.95 (2.5–3.8) | 2.8 (1.5–4.1) | 2.15 (1.2–3.8) | 0.305 |
| Tmn baseline (seconds)† | 1.0 (0.65–1.49) | 0.72 (0.47–1.37) | 0.89 (0.63–1.13) | 0.305 |
| Tmn hyperaemia (seconds)† | 0.32 (0.23–0.54) | 0.44 (0.2–0.5) | 0.32 (0.24–0.42) | 0.750 |
|
| ||||
| After PCI | ||||
| Pa hyperaemia (mm Hg) | 72 (64–81) | 71 (57–84) | 72 (65–80) | 0.794 |
| Pd hyperaemia (mm Hg) | 64 (55–69) | 62 (48–73) | 65 (52–72) | 0.884 |
| FFR | 0.86 (0.84–0.9) | 0.84 (0.82–0.87) | 0.86 (0.8–0.9) | 0.660 |
| IMR† | 14 (10–17) | 15 (9–23) | 22 (14–26) | 0.118 |
| IMRcorr† | 13 (10–17) | 14 (9–22) | 21 (13–25) | 0.060 |
| CFR | 3.6 (2.5–4.9) | 3.0 (2–4.7) | 2.3 (1.5–4.0) | 0.072 |
| Tmn baseline (seconds)† | 0.85 (0.58–1.31) | 0.61 (0.55–0.88) | 0.72 (0.52–1.22) | 0.824 |
| Tmn hyperaemia (seconds)† | 0.20 (0.17–0.3) | 0.21 (0.17–0.36) | 0.32 (0.26–0.34) | 0.045 |
Median (interquartile range); CFR = coronary flow reserve; FFR = fractional flow reserve; IMR = index of microcirculatory resistance; IMRcorr = corrected IMR; Pa = arterial pressure during hyperaemia; Pd = distal pressure during hyperaemia; Tmn = mean transit time; linear regression; †variables log-transformed before analysis.
Figure 1Changes in FFR (a), IMRcorr (b), and CFR (c) before and after PCI in relation to total stent length in LAD.